Dupilumab for treating severe asthma with type 2 inflammation

Dupilumab (Dupixent, Sanofi) has a marketing authorisation 'in adults and adolescents 12 years and older as an add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised FeNO [fractional exhaled nitric oxide] who are inadequately controlled with high dose ICS [inhaled corticosteroid] plus another medicinal product for maintenance treatment'. The definition of type 2 inflammation is as in the Global Initiative for Asthma guideline.

The dosage schedule is available in the summary of product characteristics.

The list price of dupilumab is £1,264.89 for 2 prefilled syringes 200 mg per 1.44 ml (excluding VAT; BNF online accessed November 2020).

The company has a commercial arrangement. This makes dupilumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.